Variable neutralizing antibody responses to 10 SARS-CoV-2 variants in natural infection with wild- type (B.1) virus, Kappa (B.1.617.1), and Delta (B.1.617.2) variants and COVISHIELD vaccine immunization in India: utility of the MSD platform

Variable neutralizing antibody responses to 10 SARS-CoV-2 variants in natural infection with wild- type (B.1) virus, Kappa (B.1.617.1), and Delta (B.1.617.2) variants and COVISHIELD vaccine immunization in India: utility of the MSD platform

For the efficacy of COVID-19 vaccines, emergence of variants accumulating immune-escape mutations remains a major concern. We analyzed the anti-variant (n = 10) neutralization activity of sera from COVID-19 patients infected with Wuhan (B.1), Kappa, and Delta variants and COVISHIELD vaccine recipien...

Full description

Bibliographic Details
Main Authors:	Rajashree Patil, Sonali Palkar, Akhileshchandra Mishra, Rahul Patil, Vidya Arankalle
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-06-01
Series:	Frontiers in Immunology
Subjects:	COVISHIELD MSD SARS-COV-2 variants immunogenicity ACE2 neutralization
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1181991/full

Similar Items

Neutralizing Antibodies against 10 SARS-CoV-2 Variants at Two Years Post-COVISHIELD Vaccination with Special Reference to Omicron Subvariants and Booster Administration
by: Rajashree Patil, et al.
Published: (2024-09-01)

Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion
by: Wenlin Ren, et al.
Published: (2022-04-01)

Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and B.1.617.2/Delta variant in India, 2021: a multi-centric hospital-based case-control study
by: Tarun Bhatnagar, et al.
Published: (2022-09-01)

Insights into COVID-19 Delta variant (B.1.617.2)
by: Angel Yun-Kuan Thye, et al.
Published: (2021-11-01)

Analysis of the Delta Variant B.1.617.2 COVID-19
by: Shayan Shiehzadegan, et al.
Published: (2021-10-01)

Transmission of B.1.617.2 Delta variant between vaccinated healthcare workers
by: Steven A. Kemp, et al.
Published: (2022-06-01)

Is the Delta Plus Variant (B.1.617.2/AY1) more serious than the Delta Variant?
by: Mohana Priya Kunasekaran, et al.
Published: (2021-12-01)

Genetic emergence of B.1.617.2 in COVID-19
by: L. Kirola
Published: (2021-09-01)

The neutralization of B.1.617.1 and B.1.1.529 sera from convalescent patients and BBIBP-CorV vaccines
by: Xinyi Yang, et al.
Published: (2022-09-01)

SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion
by: Mlcochova, P, et al.
Published: (2021)

Differences in Transmission between SARS-CoV-2 Alpha (B.1.1.7) and Delta (B.1.617.2) Variants
by: Camino Trobajo-Sanmartín, et al.
Published: (2022-04-01)

SARS-CoV-2 RT-PCR to Screen for B.1.617.2 (Delta) Variant of Concern
by: Kym Lowry, et al.
Published: (2022-08-01)

Effectiveness of COVID-19 Vaccines against Delta Variant (B.1.617.2): A Meta-Analysis
by: Rashidul Alam Mahumud, et al.
Published: (2022-02-01)

Large-scale synchronized replacement of Alpha (B.1.1.7) variant by the Delta (B.1.617.2) variant of SARS-COV-2 in the COVID-19 pandemic
by: Yuan Liu, et al.
Published: (2022-02-01)

Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants
by: Vladimir A. Gushchin, et al.
Published: (2021-07-01)

Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines
by: Yong Yang, et al.
Published: (2021-07-01)

Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination.
by: Chris Davis, et al.
Published: (2021-12-01)

Comparative Sensitivity of Rapid Antigen Tests for the Delta Variant (B.1.617.2) of SARS-CoV-2
by: Yuko Sakai-Tagawa, et al.
Published: (2021-10-01)

Delta variant (B.1.617.2) of SARS-CoV-2: Mutations, impact, challenges and possible solutions
by: Manish Dhawan, et al.
Published: (2022-11-01)

Impact of inactivated COVID-19 vaccines on lung injury in B.1.617.2 (Delta) variant-infected patients
by: Miao Lai, et al.
Published: (2023-03-01)

CoviWall, a whole-virion-inactivated B.1.617.2 vaccine candidate, induces potent humoral and Th1 cell response in mice and protects against B.1.617.2 strain challenge in Syrian hamsters
by: Jyotsna Dandotiya, et al.
Published: (2025-01-01)

SARS-CoV-2 infection in pediatric population before and during the Delta (B.1.617.2) and Omicron (B.1.1.529) variants era
by: Haifa Khemiri, et al.
Published: (2022-09-01)

Severe Breakthrough COVID-19 Cases during Six Months of Delta Variant (B.1.617.2) Domination in Poland
by: Piotr Rzymski, et al.
Published: (2022-04-01)

Severe breakthrough COVID-19 cases in the SARS-CoV-2 delta (B.1.617.2) variant era
by: Stephen Y Wang, et al.
Published: (2022-01-01)

Relationships between COVID-19 healthcare outcomes and county characteristics in the U.S. for Delta (B.1.617.2) and Omicron (B.1.1.529 and BA.1.1) variants
by: Alexander A. Bruckhaus, et al.
Published: (2023-11-01)

COVID-19 due to the B.1.617.2 (Delta) variant compared to B.1.1.7 (Alpha) variant of SARS-CoV-2: a prospective observational cohort study
by: Kerstin Kläser, et al.
Published: (2022-06-01)

COVID-19 outbreak trends in South Africa: A comparison of Omicron (B.1.1.529), Delta (B.1.617.2), and Beta (B.1.351) variants outbreak periods
by: Syed Mahfuz Al Hasan, et al.
Published: (2022-07-01)

Insights on the interaction of SARS-CoV-2 variant B.1.617.2 with antibody CR3022 and analysis of antibody resistance
by: Sandhya KS, et al.
Published: (2023-03-01)

Transmission chains of the first local outbreak cause by Delta VariantB.1.617.2 COVID-19 in Guangzhou, Southern China
by: Chun Chen, et al.
Published: (2024-01-01)

Infection and Transmission of SARS-CoV-2 B.1.617.2 Lineage (Delta Variant) among Fully Vaccinated Individuals
by: Leonardo C. Caserta, et al.
Published: (2022-10-01)

First Detection of SARS-CoV-2 B.1.617.2 (Delta) Variant of Concern in a Symptomatic Cat in Spain
by: Sandra Barroso-Arévalo, et al.
Published: (2022-04-01)

Changing Features of COVID-19: Characteristics of Infections with the SARS-CoV-2 Delta (B.1.617.2) and Alpha (B.1.1.7) Variants in Southern Italy
by: Daniela Loconsole, et al.
Published: (2021-11-01)

Mortality among hospitalized COVID-19 patients during surges of SARS-CoV-2 alpha (B.1.1.7) and delta (B.1.617.2) variants
by: Alireza Zali, et al.
Published: (2022-11-01)

Rapid Global Spread of the SARS-CoV-2 Delta (B.1.617.2) Variant: Spatiotemporal Variation and Public Health Impact
by: Qi Shi, et al.
Published: (2021-07-01)

First Detection of SARS-CoV-2 Delta (B.1.617.2) Variant of Concern in a Dog with Clinical Signs in Spain
by: Leira Fernández-Bastit, et al.
Published: (2021-12-01)

Effectiveness of COVID-19 Vaccines against Delta (B.1.617.2) Variant: A Systematic Review and Meta-Analysis of Clinical Studies
by: Ali Pormohammad, et al.
Published: (2021-12-01)

Olfactory dysfunction is more severe in wild-type SARS-CoV-2 infection than in the Delta variant (B.1.617.2)
by: Ludger Klimek, PhD, MD, et al.
Published: (2022-06-01)

The latent period of coronavirus disease 2019 with SARS‐CoV‐2 B.1.617.2 Delta variant of concern in the postvaccination era
by: Tao Ma, et al.
Published: (2022-07-01)

The SARS-CoV-2 Delta (B.1.617.2) variant with spike N501Y mutation in the shadow of Omicron emergence
by: Irma Salimović-Bešić, et al.
Published: (2022-12-01)

Clinical features and high-resolution chest computerized tomography findings of children infected by the B.1.617.2 variant of coronavirus disease 2019
by: Chuanjun Xu, et al.
Published: (2022-12-01)